ArticleEuropean geriatric medicine2026
Prevalence, characteristics, and prognostic associations of sarcopenia in older adults with heart failure.
Article in European geriatric medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the clinical characteristics of Japanese older sarcopenic patients with heart failure (HF) diagnosed by the Asian Working Group for Sarcopenia 2025 (AWGS 2025) criteria.
methodsThe participants were patients with HF aged ≥ 65 years who required hospitalization. At discharge, when their condition was stable, the diagnosis of sarcopenia, laboratory measurements, and echocardiography were conducted, and the occurrence of all-cause and cardiovascular mortality and hospitalization after discharge was investigated. We investigated the association between sarcopenia diagnosed by AWGS 2025 and mortality risk.
resultsWe recruited 253 patients (mean age, 82.2 years; male, 51.0%; BNP, 182.8 pg/dL). The prevalence of sarcopenia among all participants was 59.3% after adjusting for skeletal muscle mass using either method (53.8% after adjusting for height and 47.4% after adjusting for BMI). For BMI < 22 or ≥ 25 kg/m
conclusionOlder patients with HF have a high rate of sarcopenia, and sarcopenia, as defined by the AWGS 2025 criteria, is associated with an increased mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.